Greenwich LifeSciences (NASDAQ:GLSI) Given Buy Rating at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $38.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 217.46% from the stock’s current price.

Greenwich LifeSciences Trading Down 0.3 %

Shares of NASDAQ:GLSI opened at $11.97 on Tuesday. Greenwich LifeSciences has a twelve month low of $8.15 and a twelve month high of $21.44. The company has a market cap of $157.41 million, a PE ratio of -14.96 and a beta of 1.69. The company’s 50 day moving average is $12.68 and its 200 day moving average is $13.54.

Insider Buying and Selling

In related news, CEO Snehal Patel bought 3,200 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $11.12 per share, with a total value of $35,584.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,539,302 shares in the company, valued at approximately $61,597,038.24. The trade was a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired a total of 10,500 shares of company stock valued at $128,459 over the last 90 days. Insiders own 51.67% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Garden State Investment Advisory Services LLC purchased a new position in shares of Greenwich LifeSciences during the 3rd quarter valued at approximately $253,000. Barclays PLC grew its position in Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the period. Geode Capital Management LLC increased its holdings in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after buying an additional 5,861 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after acquiring an additional 4,465 shares during the period. Finally, Brown Brothers Harriman & Co. acquired a new position in shares of Greenwich LifeSciences in the fourth quarter worth about $45,000. 4.16% of the stock is owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.